• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Healthcare·ESMC
Share

Escalon Medical Corp. Stocks

$ 0.18Last Updated 29.07.2026

Issuer Rating

3/7
Performance

Favourable

Risk

High

Recommendation

Sell

Market Cap

$ 1.33M

$ 0.18
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Escalon Medical Corp. specializes in the field of ophthalmology, engaging in the development, manufacturing, promotion, and distribution of both medical devices and pharmaceutical products. Its operations span the United States and international markets. The company's product line includes a variety of diagnostic instruments for eye care. For instance, the A-Scan is designed to provide insights into the internal anatomy of the eye, while the B-Scan assists physicians in diagnosing conditions where the eye's internal media is obscured or cloudy. They also offer the UBM, a high-frequency, high-resolution ultrasound device that delivers detailed imaging of the anterior segment of the eye, alongside the Pachymeter, which accurately measures corneal thickness. Beyond diagnostic tools, Escalon supplies intraocular gas products such as C3F8 and SF6, vital for vitreoretinal surgeons who utilize them as a temporary support during detached retina surgeries. To complement this, the firm produces and distributes a patented disposable universal gas kit, ensuring the efficient delivery of these gases from the canister to the patient. Furthermore, Escalon provides disposable surgical packs tailored for vitreoretinal procedures and offers the AXIS Image management system. This web-based platform enables the seamless organization and viewing of medical images from diverse devices, manufacturers, and locations. Escalon Medical Corp. distributes its products to medical institutions through a combination of independent sales representatives, an extensive network of distributors, and its dedicated internal sales personnel. Established in 1987, the company maintains its corporate headquarters in Wayne, Pennsylvania.

Company Valuation

Undervalued
6/7

Considering past and projected metrics, the stock is 'cheaper' than its peers. Specifically, the stock is 'cheap' on P/E, overvalued on EV/EBITDA, underpriced on P/FCF.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

31.07.2026 21:35

Three Fed officials said interest rates need to be raised to combat inflation

31.07.2026 20:36

Nvidia Finds Itself in the Unfamiliar Role of an Undervalued Growth Stock — Morningstar

31.07.2026 19:29

"There's no end in sight to the rise in capital expenditures": The four Big Tech companies' investments in AI have already exceeded $1 trillion

31.07.2026 18:43

Profits at the two leading U.S. oil companies have skyrocketed. They've found a "weak spot."

31.07.2026 18:37

Novo Nordisk shares plummeted 10% after a heart drug trial failed

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026